Caption Management, LLC Blueprint Medicines Corp Call Options Transaction History

Caption Management, LLC

11 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$84.1 - $120.5 $6.07 Million - $8.7 Million	72,200 Added 252.45%	100,800 $9.32 Million
Q2 2024 Aug 14, 2024	BUY	$85.18 - $108.78 $306,648 - $391,608	3,600 Added 14.4%	28,600 $3.08 Million
Q1 2024 May 15, 2024	SELL	$73.17 - $99.79 $1.02 Million - $1.4 Million	-14,000 Reduced 35.9%	25,000 $2.37 Million
Q4 2023 Feb 14, 2024	BUY	$43.96 - $92.84 $615,440 - $1.3 Million	14,000 Added 56.0%	39,000 $3.6 Million
Q3 2023 Nov 14, 2023	BUY	$46.9 - $66.0 $1.17 Million - $1.65 Million	25,000 New	25,000 $1.26 Million
Q2 2022 Aug 15, 2022	BUY	$45.23 - $70.15 $1.13 Million - $1.75 Million	25,000 New	25,000 $1.26 Million
Q1 2022 May 13, 2022	SELL	$54.1 - $110.08 $1.35 Million - $2.75 Million	-25,000 Closed	0 $0
Q4 2021 Feb 11, 2022	BUY	$94.25 - $115.99 $2.36 Million - $2.9 Million	25,000 New	25,000 $2.68 Million
Q4 2019 Feb 13, 2020	SELL	$66.73 - $82.59 $8.48 Million - $10.5 Million	-127,100 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$72.9 - $101.41 $2.61 Million - $3.63 Million	35,800 Added 39.21%	127,100 $9.34 Million
Q2 2019 Aug 13, 2019	BUY	$73.54 - $97.8 $6.71 Million - $8.93 Million	91,300 New	91,300 $8.61 Million

351

60.3M

2.25M

1.18M

Ticker BPMC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,719,600
Market Cap $5.4B
Description
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...

Get notified when there are updates to the investment portfolio of Caption Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Caption Management, LLC with notifications on news.